Session » Measures Of Healthcare Quality Poster II: Improving Care

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1207

A Quality Improvement Intervention to Reduce 30-Day Hospital Readmission Rates Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1190

A Quality Improvement Project to Increase Documentation Efficiency in an Academic Rheumatology Practice

9:00AM-11:00AM: Abstract Number: 1213

A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology

9:00AM-11:00AM: Abstract Number: 1191

Application of the Systemic Lupus Erythematosus (SLE) Quality Indicators in Patients Attending a Young Adult Transition Program

9:00AM-11:00AM: Abstract Number: 1201

Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?

9:00AM-11:00AM: Abstract Number: 1189

Baylor Rheumatology Initiative: Developing and Guiding Engagement (BRIDGE) Transition Pathway Creation and Implementation

9:00AM-11:00AM: Abstract Number: 1194

Can an MDHAQ (Multidimensional Health Assessment Questionnaire) 60-Symptom Checklist to Monitor Early Medication Outcomes (MDHAQ/MEMO60) Detect Adverse Events of High-Risk Medications?

9:00AM-11:00AM: Abstract Number: 1192

Effect of a Clinical Decision Support System on a Quality Indicator of Glucocorticoid-induced Osteoporosis and Trends of Drug Treatment in a Japanese Hospital

9:00AM-11:00AM: Abstract Number: 1193

EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1197

Factors Associated with Clinical Disease Activity Index Adoption at an Academic Rheumatology Practice

9:00AM-11:00AM: Abstract Number: 1204

Improvements in Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody: 1-Year Results of a Phase III Trial

9:00AM-11:00AM: Abstract Number: 1211

Improving Exercise Counselling of Patients with Inflammatory Arthritis: A Quality Improvement Project

9:00AM-11:00AM: Abstract Number: 1199

Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus

9:00AM-11:00AM: Abstract Number: 1200

Influenza Vaccination Rates Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Immunosuppressive Therapy: Findings from a Large Public Hospital

9:00AM-11:00AM: Abstract Number: 1208

Outpatient Readmission in Rheumatology: A Machine Learning Predictive Model of Patient’s Return to the Clinic

9:00AM-11:00AM: Abstract Number: 1196

Patient Preference for an Electronic MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/ Routine Assessment of Patient Index Data), Which Gives Similar Results Compared to a Paper Version

9:00AM-11:00AM: Abstract Number: 1209

Patient-reported Outcome Measures in Systemic Lupus Erythematosus: Use in Clinical Practice – Preliminary Results from the Integrate Project

9:00AM-11:00AM: Abstract Number: 1206

Performance of the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) Item Profile in a Cohort of Australians with RA, OA and Other Inflammatory Arthritic Conditions

9:00AM-11:00AM: Abstract Number: 1198

Practice Based Education Program to Increase Vaccination Rate in Patients on Immunotherapeutic Agents

9:00AM-11:00AM: Abstract Number: 1212

Psychological Profile in Patients with Rheumatic Diseases in China: A Study of HADS Self-assessment with Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 1203

Psychometric Properities of the Patient Related Outcome Measure FACIT-Fatigue in Rheumatic Arthritis and Psoriatic Arthritis: A Literature Review

9:00AM-11:00AM: Abstract Number: 1195

Quantitative Physician Global Assessment of Damage And/or Distress, in Addition to Inflammation, at Routine Rheumatology Care: Documenting the Complexity of Rheumatology Patient Encounters as a Rationale for Possible Higher Reimbursement?

9:00AM-11:00AM: Abstract Number: 1205

Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)

9:00AM-11:00AM: Abstract Number: 1202

Testing Rheumatoid Arthritis Performance Measures to Optimize Treat to Target Strategies

9:00AM-11:00AM: Abstract Number: 1210

Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].